Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
  • C09B23/0075—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of an heterocyclic ring
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S435/00—Chemistry: molecular biology and microbiology
  • Y10S435/808—Optical sensing apparatus
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S435/00—Chemistry: molecular biology and microbiology
  • Y10S435/81—Packaged device or kit

Definitions

• the present invention relates to a method for binding and detecting nucleic acids and cytoskeleton elements. More specifically, the invention relates to a method for fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furan compounds.
• Fluorescence occurs when a molecule excited by light of one wavelength returns to the unexcited (ground) state by emitting light of a longer wavelength.
• the exciting and emitted light can be separated from one another using optical filters. Fluorescence has been used to visualize certain molecules (and hence structures) by light microscopy for many years, and is also used in other analytical techniques, such as flow cytometry.
• the type of fluorescent probe used in fluorescent analysis can be divided into two broad categories, those used to label covalently other probes (often antibodies) and those whose distribution or fluorescence reflects their environment and hence particular properties of a cell. Among the latter, fluorescent compounds that bind specifically to nucleic acids or to cytoskeleton structures or elements are particularly important.
• DAPI 4',6-diamidino-2-phenylindole
• DAPI 4',6-diamidino-2-phenylindole
• W. D. Wilson, et al. "The Effects of Ligand Structure on Binding Mode of Unfused Aromatic Cations with DNA” in Molecular Basis of Specificity in Nucleic Acid-Drug Interactions, Klumar Academic Publishers, Amsterdam (1990), pps. 331-353; W. D. Wilson, et al., Biochemistry 32, 4098-4104 (1993).
• DAPI also binds other cellular components, such as tubulin, resulting in RNA and tubulin staining.
• Hoechst 33258 Another stain used in fluorescent analysis applications is the bis-benzimide Hoechst 33258.
• Loontiens et al have suggested that Hoechst 33258, a closely related molecule, binds to GC-rich sequences via a self-association complex in the major groove of DNA.
• This agent also has a significant association with RNA. Wilson, et al. (1993), supra.
• DAPI and 2,5-bis(4-amidinophenyl)furan significant staining of non-DNA elements can result with Hoechst 33258.
• a first aspect of the present invention provides novel compounds of Formula (I): ##STR1## wherein: R 1 and R 2 are each independently selected from the group consisting of H, lower alkyl, cycloalkyl, aryl, hydroxyalkyl, aminoalkyl, or alkylaminoalkyl, or R 1 and R 2 together represent a C 2 to C 10 alkylene or R 1 and R 2 together are: ##STR2##
• n is a number from 1 to 3
• R 10 is H or --CONHR 11 NR 15 R 16 wherein R 15 and R 16 are each independently selected from the group consisting of H and lower alkyl;
• R 3 is H, lower alkyl, cycloalkyl, aryl, hydroxyalkyl, aminoalkyl or alkylaminoalkyl;
• A is a heterocyclic aromatic group selected from the group consisting of: ##STR3## wherein R 4 , R 5 , and R 6 are each independently selected from the group consisting of H, lower alkyl, halogen, oxyalkyl, oxyaryl, or oxyarylalkyl;
• R 12 is hydrogen, lower alkyl, hydroxy, aminoalkyl or alkylaminoalkyl.
• R 1 and R 2 together are: ##STR4## wherein n is a number from 1 to 3, and R 10 is H or --CONHR 11 NR 15 R 16 wherein R 15 and R 16 are each independently selected from the group consisting of H and lower alkyl;
• a second aspect of the present invention is a method of fluorescent detection of nucleic acids.
• the method comprises contacting to the nucleic acid a compound according to Formula (I), and exposing the nucleic acid to light to induce fluorescence of the compound of Formula (I).
• a third aspect of the invention is a method for the selective fluorescent detection of DNA in a nucleic acid mixture containing DNA and RNA.
• the method comprises the steps of (a) contacting a nucleic acid mixture with a compound according to Formula (I), and (b) exposing the nucleic acid mixture to light to induce fluorescence of the compound of Formula (I).
• Yet another aspect of the present invention is a method for the fluorescent detection of a microtubular structure.
• the method comprises contacting to the microtubular structure a compound according to Formula (I), and exposing the microtubular structure to light to induce fluorescence of the compound of Formula (I).
• Still another aspect of the present invention is a method for the simultaneous fluorescent detection of a first cellular structure and a second cellular structure in a cell, wherein said first cellular structure and said second cellular structure are different.
• the method includes (a) contacting the cell with a first fluorescent compound and a second fluorescent compound.
• the first and second fluorescent compounds are structurally different from each other, but each of the fluorescent compounds has a structure according to Formula (I).
• the first fluorescent compound selectively binds to the first structure and the second compound selectively binds to the second structure.
• the first and second fluorescent compounds have different fluorescent emission spectra.
• kits for the fluorescent detection of a cellular structure.
• the kit includes (a) a compound according to Formula (I), and (b) a solvent in an amount sufficient to form a mixture of a nucleic acid labelled with the compound of Formula (I), when the compound is contacted to a sample including a nucleic acid.
• kits which include compounds of Formula (I), (Ia) or (Ib), or their physiologically acceptable salts, as a component in the kit.
• the compounds comprise compounds of Formula (I) below: ##STR5##
• R 1 and R 2 together are: ##STR7## wherein n and R 10 are as defined above.
• R 1 and R 2 together represent a C 2 to C 10 linear, saturated alkylene. More preferrably, R 1 and R 2 together represent a C 2 to C 5 linear, saturated alkylene.
• R 1 is H and R 2 is lower alkyl, preferrably isopropyl.
• A is a heterocyclic aromatic group selected from the group consisting of: ##STR8##
• the foregoing groups representing A may be ortho, meta or para substituted with R 4 and R 5 .
• R 4 may be selected from the group consisting of H, lower alkyl, halogen, oxyalkyl, oxyaryl, or oxyarylalkyl. Preferrably, R 4 is H or lower alkyl.
• R 5 may be selected from the group consisting of H, lower alkyl, halogen, oxyalkyl, oxyaryl, or oxyarylalkyl. Preferrably, R 5 is H.
• R 12 may be selected from the group consisting of hydrogen, lower alkyl, hydroxy, aminoalkyl or alkylaminoalkyl.
• A is ##STR9## wherein R 4 and R 5 may be defined as above, but preferrably, R 4 is H, and R 5 is OCH 3 or O(C 6 H 4 )R, wherein R is H or loweralkyl. More preferrably, R is lower alkyl, and preferrably methyl.
• lower alkyl refers to C1 to C4 linear or branched alkyl, such as methyl, ethyl, propyl, butyl, isopropyl, sec-butyl, and tert-butyl.
• cycloalkyl refers to C3 to C6 cyclic alkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
• aryl refers to C3 to C10 cyclic aromatic groups such as phenyl, naphthyl, and the like, and includes substituted aryl groups such as tolyl.
• hydroxyalkyl refers to C1 to C4 linear or branched hydroxy-substituted alkyl, i.e., --CH 2 OH, --(CH 2 ) 2 OH, etc.
• aminoalkyl refers to C1 to C4 linear or branched amino-substituted alkyl, wherein the term “amino” refers to the group NR'R", wherein R' and R" are independently selected from H or lower alkyl as defined above, i.e., --NH 2 , --NHCH 3 , --N(CH 3 ) 2 , etc.
• oxyalkyl refers to C1 to C4 oxygen-substituted alkyl, i.e., --OCH 3
• oxyaryl refers to C3 to C10 oxygen-substituted cyclic aromatic groups.
• the method of the present invention is carried out by contacting or mixing a nucleic acid in a substantially pure solution thereof, or in a biological sample containing the nucleic acid with a compound of Formula (I) above and then exposing the biological sample to light to induce fluorescence of the compound of Formula (I).
• the step of exposing the biological sample to light to induce the flourescence of the compounds of Formula (I) allows anlaysis of the sample, i.e., detection of the presence of nucleic acid components contained therein.
• the method of the invention is useful in, for example, light microscopy, flow cytometry, karyotype analysis, nucleic acid detection and quantitation, electrophoresis, and the like.
• nucleic acid refers to both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Any nucleic acid may be stained, including chromosomal and extrachromosomal nucleic acids (e.g., a plasmid, an RNA virus, etc). As a result, the presence of nucleic acids in biological samples can be observed by techniques known in the art for detecting nucleic acids in a sample by fluorescent detection a of compound bound thereto, including light microscopy, confocal light microscopy, flow cytometry, and the like.
• Exemplary samples suitable for staining in accordance with the present invention typically are obtained in the form of a sample of a biological fluid or biological tissue.
• samples can be drawn from any number of biological sources from which useful diagnostic information can be obtained.
• Suitable biological fluids include, but are not limited to, blood, saliva, urine, milk, lymph fluid, and oral, nasal, and bronchial mucosa.
• Suitable tissue samples include, but are not limited to, tissue biopsy samples, such as from kidney, liver, lymph node, or other organs, and skin and other soft tissue samples (e.g., muscle). Specimens taken from subjects may be stained directly, or provided as a growth cultured from the specimen.
• the sample can also be a substantially pure solution of the nucleic acid to be detected, i.e., a solution of an intracellular component isolated from a specimen as described above.
• Samples may be collected from both plant and animal species.
• Animal species include both human and non-human species (e.g., dog, cat, rat, cow, horse, sheep, monkey, etc.).
• Other types of cells such as bacteria, fungi, protozoa, and other unicellular organisms, can also be treated in accordance with the present invention.
• cells which can be used include both eukaryotic and prokaryotic.
• cells are stained by incubation under appropriate conditions with the fluorescent compound according to Formula (I).
• staining by the compounds according to Formula (I) can be achieved by following standard protocols known in the art for DAPI staining as described in O. Miller, Principles and Practices in Medical Genetics (Longman Group Limited, New York 1983) and D. Silvonen, ACT Cytogenetic Lab Manual (University of California, San Francisco 1980).
• the sample can be stained using standard protocols for bis-benzimide staining as is also known in the art. See, e.g., Human Cytogenetics, Volume 1, Constitutional Analysis, pg 113 (D. Rooney and B. Czepulkowski, Eds., IRL Press at Oxford University Press).
• the sample is contacted or mixed with an amount of a compound of Formula (I) to bind the compound with nucleic acid in the sample. Since one molecule of the compound of Formula (I) generally binds to four base pairs double stranded nucleic acid, any mount sufficient to produce a detectable signal may be used. Thus, the proportion or ratio of the amount of a compound of Formula (I) to a target to be detected may be about 1:4, 1:8, 1:16, 1:32 or more, depending among other things on how the target is to be detected. If desired, excess amounts of the compound can optionally be washed away after staining. As will be appreciated by the skilled artisan, washing is not required for analytical techniques wherein the sample is provided as a substantially pure solution of the nucleic acid as described above, analyzed using, for example, a fluorimeter.
• the compound can be provided in an aqueous solution, and the contacting step can be carried out by simply immersing the sample with the solution. There is, however, no need to store the solution in the dark to preserve the stability of the compounds, as has been reported as necessary for DAPI.
• a solution can have a minimum final concentration of about 0.01 micromolar ( ⁇ M), although the solution can have a final concentration between about 0.01 and 5, 10, or 25 micromolar or more.
• the duration of contact between the sample and the compound can vary widely depending on the contacting technique, but is generally between about 30 seconds and two hours, and is preferably between about 1 and 15 minutes, when the sample is immersed in a solution in the concentrations described above.
• the sample can also be stained using combinations of fluorochromes.
• fluorescence from compounds according to Formula (I) and from other compounds can be detected simultaneously for such compounds fluorescent detection at different wavelengths.
• a combination of fluororchromes can be selected to amplify the fluorescent signal using fluorescent energy transfer techniques.
• the compounds of Formula (I) may be modified to remove DNA binding affinity, without removing convenient conjugation sites to which other entities may attach.
• One suitable entity to which compounds of Formula (I) may be conjugated includes oligonucleotides of both DNA and RNA. Such conjugates of the compound of Formula (I) may be useful for anti-sence reagents, probes for hybridization studies, bandshift assays of DNA-protein complexes, or for primers for fluorescent DNA sequencing and PCR applications. Additionally, the compounds of Formula (I) may be conjugated to numerous reagents for in situ labeling studies. Exemplary reagents include antibodies for immunohistochemistry, and size marker molecules to measure volume.
• the compounds of Formula (I) may also be conjugated to reagents for the purpose of forming substrates for measurement of enzyme activities that either gain or lose fluorescence upon enzyme activity, e.g., proteases, phosphatases, kinases, antibiotic inactivation, nucleases, and carbohydrates.
• the conjugated compounds of Formula (I) may or may not have to be unconjugated in situ to produce flourescence. In other words, the conjugated compounds of Formula (I) may retain flourescence despite conjugation, or may fluoresce upon cleavage from the conjugate.
• the exposing step of the method of the invention can be carried out by known techniques suitable for inducing the compound of Formula (I) to produce a detectable signal. Generally this will comprise exposing the biological sample to ultraviolet light at a frequency which will induce fluorescence of the compound of Formula (I) (e.g., 210-380 nm). The only limitation is that the intracellular component to be detected, i.e., nucleic acid, is not destroyed by the light frequency and/or intensity.
• the wavelength selected to induce fluorescence of the compound is known in the art as the "excitation maximum," i.e., that wavelength which is absorbed by a molecule and excites that molecule to a higher electronic state.
• the excitation wavelength is in the ultraviolet range.
• the molecule passes from the higher to a lower electronic state, the molecule emits a type of visible radiation, i.e., fluorescence, of a wavelength referred to as the "emission maximum.” It is the fluorescence that is detected in the present invention.
• the detectable signal emitted by the compound can be detected using techniques known in the art, for example by observation with the human eye, using electronic means for detecting a generated wavelength, and the like.
• the wavelength of fluorescence is sufficiently removed from that of the exciting light to allow good separation of the two wavelengths by optical filters.
• Filtered light can be used, for example, to select the desired wavelength of exciting light on the input side, and/or to select the appropriate range of emission wavelengths for measurement of fluorescence peak or maxima.
• Another aspect of the invention relates to methods for binding cytoskeleton elements of a cell in a sample and detecting the presence of the same.
• a compound according to Formula (I) above or a physiologically acceptable salt thereof is contacted or mixed with a cytoskeleton element in a substantially pure solution thereof, or in a biological sample containing the cytoskeleton element.
• the sample is exposed to light at a frequency which induces fluorescence of the compound of Formula (I) so as to allow analysis of the sample, i.e., detection of the presence of cytoskeleton elements components contained therein.
• This aspect of the invention is useful in, for example, light microscopy, including confocal light microscopy, biochemical assays, and the like.
• This aspect of the method of the invention can be conducted as described above in more detail with regard to the fluorescent detection of nucleic acids.
• cytoskeleton elements refers to protein fibers comprising the structural framework of a cell.
• the present invention is particularly preferred for use with microtubular structures as the cytoskeleton element, which is particularly sensitive to this method.
• tubulin is a major protein of microtubules.
• this aspect of the invention can provide techniques for determining disruption of the polymerization of tubulin in forming microtubular structures.
• samples are preferably immobilized on a solid support prior to the introduction of the compounds of the invention (the staining reagents).
• Any solid support can be used, with exemplary solid supports including microscope slides, wall surfaces of reaction wells, test tubes, and cuvettes, and beads.
• the solid support can be formed of any material known to be suitable to those skilled in this art, including glass, polystyrene, polyethylene, polypropylene, and cross-linked polysaccharides.
• the sample is fixed to a glass microscope slide.
• the sample can be fixed to the solid support by any suitable procedure, such as air-drying or chemical or heat treatment, that does not interfere with subsequent observation of the sample. It is preferred that the slide be immobilized in such a manner that it can be observed by light microscopy.
• the sample can be stained with the compounds according to Formula (I) by following standard protocols known in the art for DAPI or bis-benzimide staining, as noted above.
• the sample is washed after staining to remove excess amounts of the compound of Formula(I) so as to remove background interference and to improve resolution of the sample.
• the staining process is initiated by contacting the sample with a compound according to Formula (I) in an amount sufficient to bind nucleic acid or cytoskeleton elements in the sample, for example, by immersing the sample with an aqueous solution of the compound.
• the amount of the compound of Formula (I) and duration of contacting can be as described above.
• the thus prepared sample slides can be analyzed using known fluorescent techniques, such as fluorescent microscopy.
• the sample can be viewed using a photomicroscope equipped with an ultraviolet (UV) source such as a mercury or xenon lamp and appropriate filters, and the images photographed using conventional techniques.
• UV ultraviolet
• the cells are illuminated with a UV light source, which is the source of excitation, and must be capable of producing specific wavelengths that can be used to excite the fluorescent compounds of the invention.
• Flow cytometry is a technique for making rapid measurements on particles or cells as they flow in a fluid stream one by one through a sensing point.
• the aim of sample preparation is to produce a suspension of disperse particles stained in a specific way which will pass through the system without disrupting the smooth flow of fluid or blocking tubes or orifices.
• Sample preparation is in accordance with known techniques for flow cytometry.
• the sample is contacted with a compound of Formula (I) following the protocols set forth above with regard to concentrations and duration of contact.
• the sample is contacted with the compound of Formula (I) prior to injecting or delivering the sample to the fluid stream of the flow cytometry system to provide a suspension of disperse particles.
• body fluids such as blood containing individual cells, can be stained and processed directly on the flow cytometer to measure absolute cellular content of the macromolecule in question.
• Preparation of solid tissues can be direct, i.e., simple chopping and teasing of the organ followed by sieving and density gradient centrifugation. Other tissues can require enzymatic digestion.
• the sample suspension is injected into the center of an enclosed channel through which liquid is flowing.
• the cells pass through the detection point, where the cell is illuminated.
• the light is the source of excitation, and the light source must be capable of producing specific wavelengths that can be used to excite the fluorescent compounds of the invention.
• the scattered and fluorescent light generated by cells passing through the illuminating beam is collected by photodetectors which convert the photon pulses into electronic signals. Further electronic and computational processing results in graphic display and statistical analysis.
• the compounds of Formula (I) are prepared generally as indicated in the reaction scheme below by: (a) cyclodehydrative furanization of 1,4-diketones (1) according to the procedure taught by R. E. Lutz, et al., J. Am. Chem. Soc.
• step (c) above can be substituted by a thermolysis step, wherein the bis-nitrile (3) is transformed into a compound of Formula (I) using heat to fuse a diamine salt, i.e., amine hydrochloride, directly with the bis-nitrile, as exemplified by Example 5 below.
• a diamine salt i.e., amine hydrochloride
• the compounds used in the present invention may be present as physiologically acceptable salts (e.g., salts which are not so unduly disruptive of the sample so that the compound is not capable of being detected).
• physiologically acceptable salts include the glauconite, lactate, acetate, tartrate, citrate, maleate, furmarate, phosphate, borate, nitrate, sulfate, and hydrochloride salts.
• the salts of the present invention may be prepared, in general, by reacting two equivalents of the amidine base compound with the desired acid, in solution. After the reaction is complete, the salts are crystallized from solution by the addition of an appropriate amount of solvent in which the salt is insoluble.
• RNA molecules according to Formula (I) are similar to DAPI and Hoechst 33258.
• Compounds according to Formula (I) can bind double-stranded DNA strongly and with high specificity, with essentially no binding to RNA.
• 2,5-bis 4-(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-yl) phenyl! furan has essentially no detectable affinity for RNA.
• the compounds of Formula (I) emit a blue color of a slightly different wavelength than that emitted by DAPI, and there can be less light scatter than that observed with DAPI. This can result in delineation of more detail.
• a staining kit comprises reagents in amounts sufficient to carry out the aforementioned steps, i.e., a compound according to Formula (I).
• the reagents should be provided in a form suitable for long-term storage such as a crystalline powder or an aqueous solution.
• the kit will generally include, inter alia, vials for storing the reagents, mixing vessels, and an instruction sheet that sets forth the aforementioned steps.
• the reagents may also include ancillary agents such as buffering agents and the like.
• the kit may further include, where necessary, agents for reducing background interference in a test, control reagents, apparatus for conducting a test, and the like.
• the copper salts must be removed since they carry over to the bis-amidines from which they are difficult to purify.
• a convenient method to detect the presence of copper salts is a flame test. Evaporation of the eluent from the alumina column and recrystallization from ethanol gave 3.5 g (65%), mp 294°-295° C.
• 2,5-Bis(4-cyanophenyl)furan (3 g, 0.011 mol) (prepared as described in Example 1) in a mixture of 100 mL of dioxane and 25 mL of absolute ethanol was saturated with dry HCl gas at 5° C. The solution was placed in a pressure bottle and shaken for 3 days (room temperature). An intermediate product, an imidate ester hydrochloride, precipitated as a yellow solid, was filtered and dried under vacuum at room temperature overnight. The IR spectra of the imidate ester hydrochloride was free of adsorption for nitrile and it was used directly without further characterization.
• Example 3 In a similar manner as set forth in Example 3, an imidate ester hydrochloride synthesized as described above in Example 2 was reacted with 1,3-propanediamine to yield (90%) of the 2,5-Bis 4-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl! furan, mp 430°-431° C. dec.
• This compound was obtained by an alternate method from 2,5-bis(4-cyanophenyl) furan.
• dinitrile 0.5 g, 1.9 mmole
• ethylenediamine dihydrochloride 4.9 g, 37 mmole
• ethylenediamine 2.5 ml, 37 mmole
• a mixture of the dinitrile, ethylenediamine dihydrochloride, and ethylenediamine was maintained at 300°-310° C. for 10 minutes and then dissolved in hot water. Yellow crystals separated on cooling. The compound was recrystallized from boiling water. Yield, 208 mg (24%).
• the bis-methoxyethanol imidate ester (1 g, 0.002 mole), and 1,4-diaminobutane (0.5 g, 0.0057 mole) in 10 ml of 1,2-dimethoxyethane were refluxed for 2 days.
• the solvent was removed in vacuum and water was added.
• the precipitate was filtered, washed with water and dried in a vacuum oven (m.p. >300° C.).
• the free base reaction product of the bis-methoxyethanol imidate ester and 1,4-diaminobutane was converted into the hydrochloride (m.p. >300° C.) by hydrogen chloride in methanol.
• the filtrate was neutralized using 2N sodium hydroxide and another portion of the free base was obtained.
• Example 2 Dry isopropylamine (0.47 g, 0.008 mole) was added to a suspension of an imidate ester as described in Example 2 (1.3 g, 0.003 mole) in 45 ml absolute ethanol. Within 0.5 hr the imidate ester dissolved and the mixture of the imidate ester and isopropylamine became colored. After ca. 3 hr a white solid precipitated; the slurry was stirred overnight at room temperature. The solvent was removed under reduced pressure, diluted with water, filtered and washed with water.
• 1-(4-tolyloxyl)-1,2-bis(4-bromobenzoyl)ethylene To a solution of 1,2-dibromo-1,2-di(4-bromobenzoyl) ethane (11.1 g, 0.02 mole) in 35 ml of THF was added a suspension of sodium 4-methyl phenoxide prepared from 0.92 g (0.04 mole) Na and 4.32 g (0.04 mole) 4-methylphenol in 30 ml THF by refluxing for 4-5 hr!. The yellow mixture was refluxed for 2-3 hr (TLC followed) after which the THF was removed under reduced pressure.
• the imidate ester was resuspended into 25 ml dry ethanol and heated at gentle reflux with 0.31 g (0.0053 mole) ethylenediamine for 12 hr. The excess ethanol was removed by distillation and the residue was treated with water, basified with 1M NaOH (stirring and cooling). The yellow precipiate was filtered, washed with water, dried and recrystallized from boiling ethanol to yield 0.6 g (74%), mp 156°-7° C.
• 1,2-Bis(4-bromobenzoyl)-1-methoxyethane To a solution of 1,2-dibromo-1,2-di(4-bromobenzoyl) ethane (11.1 g, 0.02 mole) in 150 mL dry methanol was added a solution of sodium methoxide in methanol (0.92 g sodium in 50 mL methanol). The yellow brown mixture was refluxed for 1-1.5 hr. The solvent was removed by distillation, the residue was suspended in water and the mixture was extracted with 100 mL chloroform. The chloroform extract was washed with water, dried (Na 2 SO 4 ) and concentrated.
• the free base (0.6 g, 0.0015 mole) was suspended in 3 mL of dry ethanol and was treated with 6 mL ethanolic HCl and heated gently at 65° C. for 1 hr.
• the yellow solution was diluted with 50 mL dry ether and filtered, washed with dry ether and dried in vacuo at 75° C. for 12 hr.
• the yield of yellow solid was 0.55 g (80%), mp>310° C. (dec.).
• DAPI Hoechst 33258, and distamycin were obtained from Sigma Chemical Co.
• Giardia lamblia were cultured by standard methods as previously described (C. A. Bell, et al., Agents and Chemother. 37, 2668-2673 (1993)), released from the culture tubes by chilling, and washed with HBSS - (Hanks Balanced Salt Solution, available from Sigma Chemical Co.) buffer. The organisms were then incubated with the dye for five minutes and washed once with HBSS - buffer before mounting for microscopy. Metaphase chromosome spreads were prepared from human lymphocytes by standard methods. Staining by all of the dyes followed standard protocols used for DA (distamycin)/DAPI staining of C bands (O. Miller, Principles and Practices in Medical Genetics (Longman Group Limited, New York 1983) and D. Silvonen, ACT Cytogenetic Lab Manual (University of California, San Francisco (1980)).
• MacIlvaine's buffer pH 7.5
• MacIlvaine's buffer was prepared as known by mixing an anhydrous citric acid solution (0.2M, 19.2 g/liter) and an anhydrous sodium phosphate dibasic (Na 2 HPO 4 ) solution (0.2M, 28.4 g/liter)).
• the slide was stained using DAPI (0.2 ⁇ g/ml) for about 10 minutes and rinsed with MacIlvaine's buffer. This same staining procedure was followed for staining with the compounds of Formula (I), except that the slide was stained using 0.02 ⁇ g/ml of the compound.
• Tissues were mounted in either HBSS - buffer or glycerol on a slide and covered with a glass coverslip. Special materials were not needed.
• the samples were viewed under a Nikon photomicroscope equipped with UV optics (filters with excitation of 360 nm and emission of 460 nm) and neofluor lenses. The images were photographed with either Ektachrome 1600 ASA film or Technical Pan 400 ASA black and white film. Exposure times were 0.1 to 5 seconds.
• furan; 2,5-bis ⁇ 4-(N-isopropyl)amidino!phenyl ⁇ furan; and 2,5-bis(4-amidinophenyl)furan produced substantially similar staining patterns to that of DAPI.
• the furan dyes emit a blue color of slightly different wavelength than that emitted by DAPI. This can result in less light scatter than that observed with DAPI, and thus there is the potential to delineate more detail.
• special handing and/or storage protocols are not needed with the furan dyes.
• the dicationic furans have been also examined in many other types of tissue such as bacteria, yeast, plants, and tissue culture cells.
• their DNA detection sensitivity is comparable to that of DAPI with the advantage that their deeper blue color and DNA specificity properties can elucidate more detail.
• nucleic acid binding parameters were determined for these compounds in the same manner as the others. Specifically, nucleic acid binding parameters were determined using thermal melting (Tm) studies using a Cary 219 spectrophotometer interfaced to an Apple IIe microcomputer.
• Table I compares the DNA and RNA affinities of the fluorescent dyes 2,5-bis(4-amidinophenyl)furan (DB75);
• the dyes either with or without DNA or RNA present were scanned for with absorption maxima in a Shimadzu double-beam spectrophotometer. The determination of their fluorescent excitation and emission maxima were determined on an LKB fluorimeter. The absorbance maxima, excitation coefficients, excitation maxima, and emission maxima are shown in Table II below.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Hematology (AREA)
• Medicinal Chemistry (AREA)
• Biomedical Technology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Analytical Chemistry (AREA)
• Physics & Mathematics (AREA)
• Food Science & Technology (AREA)
• Biochemistry (AREA)
• Cell Biology (AREA)
• Plural Heterocyclic Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Saccharide Compounds (AREA)
• Luminescent Compositions (AREA)
• Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Priority Applications (19)

Applications Claiming Priority (1)

Related Child Applications (4)

Publications (1)

Family

ID=22899218

Family Applications (2)

Family Applications After (1)

Country Status (10)

Cited By (15)

Families Citing this family (19)

Citations (2)

• 1994
  • 1994-05-06 US US08/238,766 patent/US5723288A/en not_active Expired - Fee Related
• 1995
  • 1995-05-05 JP JP07529154A patent/JP3098545B2/ja not_active Expired - Fee Related
  • 1995-05-05 AU AU24369/95A patent/AU699223B2/en not_active Ceased
  • 1995-05-05 BR BR9507616A patent/BR9507616A/pt unknown
  • 1995-05-05 CN CN95193470A patent/CN1151209A/zh active Pending
  • 1995-05-05 EP EP95918418A patent/EP0758453A1/fr not_active Ceased
  • 1995-05-05 WO PCT/US1995/005713 patent/WO1995030901A1/fr not_active Application Discontinuation
  • 1995-05-05 CA CA002189125A patent/CA2189125A1/fr not_active Abandoned
  • 1995-05-05 HU HU9603078A patent/HUT76440A/hu unknown
  • 1995-05-05 NZ NZ285309A patent/NZ285309A/xx unknown
  • 1995-05-30 US US08/453,232 patent/US5594138A/en not_active Expired - Lifetime

Patent Citations (2)

Non-Patent Citations (50)

Also Published As

Similar Documents

Legal Events